GLP-1 Receptor Agonists’ Impact on Fertility - A Review
DOI:
https://doi.org/10.12775/QS.2025.38.58325Keywords
GLP-1 analog, fertility, obesity, PCOSAbstract
Purpose of Research: The aim of the research is to summarize the impact of GLP-1 analogs on fertility according to clinical studies, particularly in obese or overweight women with PCOS.
Research Materials and Methods: The study is built upon an analysis of current literature, clinical trials, meta-analyses, and systematic reviews as well as press reports from various sources. Data were collected from studies examining the effects of obesity on fertility, as well as the impact of GLP-1 analogs on both fertility and obesity.
Basic Results: GLP-1 analogs promote weight management among obese and overweight patients leading to improvement in their fertility. Furthermore, they improve pregnancy rates in women with PCOS, although further examination is needed.
Conclusions: We observe, GLP-1 analogs are often used in regulation of type 2 diabetes. They have proven their ability to impact a variety of hormonal as well as metabolic pathways. They manage glucose metabolism, appetite, as well as insulin secretion. Alongside their metabolic influence, research demonstrates that GLP-1 analogs may have an effect on the reproductive system, involving fertility via metabolic and hormonal pathways.
References
1. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Vol. 46, Molecular Metabolism. 2021.
2. Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: Systematic review and network meta-analysis. BMJ. 2024;
3. Yaribeygi H, Sathyapalan T, Sahebkar A. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Vol. 234, Life Sciences. 2019.
4. Sandoval D, Sisley SR. Brain GLP-1 and insulin sensitivity. Vol. 418, Molecular and Cellular Endocrinology. 2015.
5. Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3).
6. Aldawsari M, Almadani FA, Almuhammadi N, Algabsani S, Alamro Y, Aldhwayan M. The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials. Vol. 16, Diabetes, Metabolic Syndrome and Obesity. 2023.
7. Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: Unraveling the diverse neural circuitry. Vol. 310, American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 2016.
8. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Vol. 57, Molecular Metabolism. 2022.
9. Welsh A, Hammad M, Piña IL, Kulinski J. Obesity and cardiovascular health. Vol. 31, European Journal of Preventive Cardiology. 2024.
10. Campbell JM, Lane M, Owens JA, Bakos HW. Paternal obesity negatively affects male fertility and assisted reproduction outcomes: A systematic review and meta-analysis. Vol. 31, Reproductive BioMedicine Online. 2015.
11. Snider AP, Wood JR. Obesity induces ovarian inflammation and reduces oocyte quality. Vol. 158, Reproduction. 2019.
12. Vander Borght M, Wyns C. Fertility and infertility: Definition and epidemiology. Vol. 62, Clinical Biochemistry. 2018.
13. Chambers TJ, Anderson RA. The impact of obesity on male fertility. Vol. 14, Hormones. 2015.
14. Jensen TK, Andersson AM, Jørgensen N, Andersen AG, Carlsen E, Petersen JH, et al. Body mass index in relation to semen quality and reproductive hormones among 1,558 Danish men. Fertil Steril. 2004;82(4).
15. Salas-Huetos A, Maghsoumi-Norouzabad L, James ER, Carrell DT, Aston KI, Jenkins TG, et al. Male adiposity, sperm parameters and reproductive hormones: An updated systematic review and collaborative meta-analysis. Vol. 22, Obesity Reviews. 2021.
16. Fariello RM, Pariz JR, Spaine DM, Cedenho AP, Bertolla RP, Fraietta R. Association between obesity and alteration of sperm DNA integrity and mitochondrial activity. BJU Int. 2012 Sep;110(6):863–7.
17. Moon KH, Park SY, Kim YW. Obesity and erectile dysfunction: From bench to clinical implication. Vol. 37, World Journal of Men?s Health. 2019.
18. Brewer CJ, Balen AH. The adverse effects of obesity on conception and implantation. Vol. 140, Reproduction. 2010.
19. Broughton DE, Moley KH. Obesity and female infertility: potential mediators of obesity’s impact. Vol. 107, Fertility and Sterility. 2017.
20. Childs G V., Odle AK, MacNicol MC, MacNicol AM. The Importance of Leptin to Reproduction. Vol. 162, Endocrinology (United States). 2021.
21. Silvestris E, de Pergola G, Rosania R, Loverro G. Obesity as disruptor of the female fertility. Vol. 16, Reproductive Biology and Endocrinology. 2018.
22. Muhammad T, Wan Y, Lv Y, Li H, Naushad W, Chan WY, et al. Maternal obesity: A potential disruptor of female fertility and current interventions to reduce associated risks. Vol. 24, Obesity Reviews. 2023.
23. Ye J. Mechanisms of insulin resistance in obesity. Vol. 7, Frontiers of Medicine in China. 2013.
24. Wu H, Ballantyne CM. Metabolic Inflammation and Insulin Resistance in Obesity. Vol. 126, Circulation Research. 2020.
25. Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Vol. 137, Biomedicine and Pharmacotherapy. 2021.
26. Collée J, Mawet M, Tebache L, Nisolle M, Brichant G. Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments. Vol. 37, Gynecological Endocrinology. 2021.
27. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Vol. 37, Endocrine Reviews. 2016.
28. van der Spuy ZM, Dyer SJ. The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome. Vol. 18, Best Practice and Research: Clinical Obstetrics and Gynaecology. 2004.
29. Kicińska AM, Maksym RB, Zabielska-Kaczorowska MA, Stachowska A, Babińska A. Immunological and Metabolic Causes of Infertility in Polycystic Ovary Syndrome. Vol. 11, Biomedicines. 2023.
30. De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: An update. Vol. 14, Reproductive Biology and Endocrinology. 2016.
31. Jensterle M, Janez A, Fliers E, Devries JH, Vrtacnik-Bokal E, Siegelaar SE. The role of glucagon-like peptide-1 in reproduction: From physiology to therapeutic perspective. Hum Reprod Update. 2019;25(4).
32. Outeiriño-Iglesias V, Romani-Perez M, Gonzalez-Matias LC, Vigo E, Mallo F. GLP-1 increases preovulatory LH source and the number of mature follicles, as well as synchronizing the onset of puberty in female rats. Endocrinology (United States). 2015;156(11).
33. Jensterle M, Podbregar A, Goricar K, Gregoric N, Janez A. Effects of liraglutide on obesity-associated functional hypogonadism in men. Endocr Connect. 2019;8(3).
34. Tao X, Zhang X, Ge SQ, Zhang EH, Zhang B. Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide. Int J Clin Exp Pathol. 2015;8(7).
35. Niafar M, Pourafkari L, Porhomayon J, Nader N. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Vol. 293, Archives of Gynecology and Obstetrics. 2016.
36. Piltonen TT. Polycystic ovary syndrome: Endometrial markers. Vol. 37, Best Practice and Research: Clinical Obstetrics and Gynaecology. 2016.
37. Artunc-Ulkumen B, Pala HG, Pala EE, Yavasoglu A, Yigitturk G, Erbas O. Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats. Gynecological Endocrinology. 2015;31(3).
38. Khan D, Ojo OO, Woodward ORM, Lewis JE, Sridhar A, Gribble FM, et al. Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice. Biomolecules. 2022;12(12).
39. Liu X, Zhang Y, Zheng SY, Lin R, Xie YJ, Chen H, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017;87(6).
40. Salamun V, Jensterle M, Janez A, Bokal EV. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179(1).
41. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 2008;93(7).
42. Nylander M, Frøssing S, Clausen H V., Kistorp C, Faber J, Skouby SO. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017;35(1).
43. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
44.https://edition.cnn.com/2024/05/08/health/ozempic-babies-pregnancy/index.html
46. https://www.washingtonpost.com/wellness/2024/04/05/ozempic-babies-weight-loss-fertility/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Joanna Wojda, Katarzyna Lesiczka-Fedoryj, Anna Walczak, Zuzanna Kościuszko, Adam Sobiński, Matylda Czerwonka, Katarzyna Kurza, Julianna Podolec, Silvia Ciraolo, Agnieszka Kulczycka-Rowicka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 217
Number of citations: 0
